Placebo News and Research

RSS

ArQule to present tivantinib clinical trial data at ASCO 2014

ArQule, Inc. today announced that tivantinib will be included in seven presentations during the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held from May 30, 2014 to June 3, 2014 in Chicago, Illinois.

31 May 2014

Review on effects of pre-referral rectal artesunate for people with severe malaria

Researchers from the Cochrane Infectious Diseases Group, hosted at LSTM, conducted an independent review of the effects of pre-referral rectal artesunate for people with severe malaria, published in the Cochrane Library today.

30 May 2014

Trimel announces top-line results of Phase II clinical trial evaluating efficacy of Tefina

Trimel Pharmaceuticals Corporation (TSX: TRL) announced today top-line results of its Phase II clinical trial evaluating the efficacy and safety of Tefina™, a "use-as-required" testosterone nasal gel for the treatment of Female Orgasmic Disorder (FOD).

28 May 2014

Estrogen therapy and venlafaxine treatment effective for hot flashes, night sweats

A new research study from Brigham and Women's Hospital (BWH) that compares low-dose oral estrogen and low-dose non-hormonal venlafaxine hydrochloride extended release (XR) to placebo were both found effective in reducing the number of hot flashes and night sweats reported by menopausal women.

27 May 2014

EMA's CHMP gives positive opinion for PTC Therapeutics' Translarna

PTC Therapeutics, Inc. today announced that following its request for re-examination, the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion regarding the company's application for a conditional marketing authorization of Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients aged five years and older.

23 May 2014

Eisai launches new class of epilepsy treatment Fycompa in France

Fycompa (perampanel), the first in an entirely new class of treatment for partial onset seizures (the most common form of epilepsy), has today received reimbursement approval from the Comité Economique des Produits de Santé.

22 May 2014

Viewpoints: Michelle Nunn's confusing stance on health law; seeking to assess Wis. wxperiment

In Georgia, where the Republican Senate primary takes place today, the early campaign season has been spent with the candidates vying to out-conservative each other.

22 May 2014

Phase 3 data of VIVACITO study evaluating effect of T+O FDC in COPD presented at ATS conference

Boehringer Ingelheim today presented results of the VIVACITO® (NCT01559116) study, the first Phase 3 data to be reported from the TOviTO® clinical trial program, evaluating the effect of the fixed-dose combination of tiotropium and olodaterol (T+O FDC) delivered via the Respimat® inhaler on lung function in people with chronic obstructive pulmonary disease (COPD).

22 May 2014

Physiotherapy for hip osteoarthritis questioned

Hip osteoarthritis is a prevalent and costly chronic musculoskeletal condition. Clinical guidelines recommend physiotherapy as treatment, although its effectiveness has never been proven.

22 May 2014

Researchers explore perceptions of cancer trials on ‘International Clinical Trials Day’

A new article published by ecancermedicalscience on May 20th addresses the question of why cancer patients are afraid of participating in potentially life-saving clinical trials.

21 May 2014

Edison Pharmaceuticals' EPI-743 granted orphan designation for Leigh syndrome in Japan

Edison Pharmaceuticals has announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted Orphan Designation to EPI-743 for the treatment of Leigh syndrome.

21 May 2014

New antibody can improve quality of life for individuals with asthma

Researchers at St. Joseph's Healthcare Hamilton and McMaster University have successfully tested an antibody that can improve the quality of life for individuals with asthma by relieving inflammation in the lungs.

21 May 2014

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).

21 May 2014

Aradigm receives QIDP designation for its inhaled antibiotic candidate, Pulmaquin

Aradigm Corporation (the "Company") today announced that the U.S. Food and Drug Administration (FDA) has designated the Company's lead inhaled antibiotic candidate, Pulmaquin®, as a Qualified Infectious Disease Product (QIDP).

20 May 2014

Sanofi presents Phase II trial results for investigational vaccine for prevention of CDI

Sanofi Pasteur, the vaccines division of Sanofi, presented Phase II (H-030-012) trial results for an investigational vaccine for the prevention of Clostridium difficile infection at the 114th General Meeting of the American Society for Microbiology.

20 May 2014

Novel drug for patients with inoperable CTEPH shows improvement in international trial

After a year of being treated with a novel drug, patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) and those with persistent or recurrent pulmonary hypertension after an operation for the disease showed sustained improvement in a multicenter, international trial presented at the 2014 American Thoracic Society International Conference.

20 May 2014

Placebo News and Research

ArQule to present tivantinib clinical trial data at ASCO 2014

Review on effects of pre-referral rectal artesunate for people with severe malaria

Trimel announces top-line results of Phase II clinical trial evaluating efficacy of Tefina

Estrogen therapy and venlafaxine treatment effective for hot flashes, night sweats

EMA's CHMP gives positive opinion for PTC Therapeutics' Translarna

Eisai launches new class of epilepsy treatment Fycompa in France

Viewpoints: Michelle Nunn's confusing stance on health law; seeking to assess Wis. wxperiment

Phase 3 data of VIVACITO study evaluating effect of T+O FDC in COPD presented at ATS conference

Physiotherapy for hip osteoarthritis questioned

Researchers explore perceptions of cancer trials on ‘International Clinical Trials Day’

Edison Pharmaceuticals' EPI-743 granted orphan designation for Leigh syndrome in Japan

New antibody can improve quality of life for individuals with asthma

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Aradigm receives QIDP designation for its inhaled antibiotic candidate, Pulmaquin

Sanofi presents Phase II trial results for investigational vaccine for prevention of CDI

Novel drug for patients with inoperable CTEPH shows improvement in international trial

Juventas presents positive trial results of JVS-100 drug delivered by Biocardia’s Helix transendocardial system

GSK reports positive results from Incruse Ellipta and Advair Diskus combination therapy in COPD patients

Study compares effectiveness of duloxetine and fluoxetine in children with MDD

Ring pessary for OAB as effective as nonsurgical therapies

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News